[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neurologic-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neurologic-disorders":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,73,107,132,159,195],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":53,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100270060","neurologic-stem-cell-treatment-study-100270060",false,"NCT02795052","Neurologic Stem Cell Treatment Study","Neurologic Bone Marrow Derived Stem Cell Treatment Study","NEST","Inclusion Criteria:\n\n1. Have documented functional damage to the central or peripheral nervous system unlikely to improve with present standard of care.\n2. Be at least 6 months post-onset of the disease.\n3. If under current medical therapy (pharmacologic or surgical treatment) for the condition be considered stable on that treatment and unlikely to have reversal of the associated neurologic functional damage as a result of the ongoing pharmacologic or surgical treatment.\n4. In the estimation of Dr. Weiss and the neurologists have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.\n5. Be over the age of 18 and capable of providing informed consent.\n6. Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure. Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.\n\nExclusion Criteria:\n\n1. All patients must be capable of an adequate neurologic examination and evaluation to document the pathology. This will include the ability to cooperate with the exam.\n2. Patients must be capable and willing to undergo follow up neurologic exams with the sub-investigators or their own neurologists as outlined in the protocol.\n3. Patients must be capable of providing informed consent.\n4. In the estimation of Dr. Weiss the BMSC collection and treatment will not present a significant risk of harm to the patient's general health or to their neurologic function. .\n5. Patients who are not medically stable or who may be at significant risk to their health undergoing the procedure will not be eligible.\n6. Women of childbearing age must not be pregnant at the time of treatment and should refrain from becoming pregnant for 3 months post treatment.","ALL","18 Years",{"count":20,"type":21},500,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1\u002F3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http:\u002F\u002Fmdstemcells.com\u002Fnest\u002F",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52],"Neurologic Disorders","Nervous System Diseases","Neurodegenerative Diseases","Neurological Disorders","Stroke","Traumatic Brain Injury","Cadasil","Chronic Traumatic Encephalopathy","Cerebral Infarction","Cerebral Ischemia","Cerebral Stroke","Cerebral Hemorrhage","Parkinson","Multi-System Degeneration","MSA - Multiple System Atrophy","Progressive Supranuclear Palsy","ALS","Amyotrophic Lateral Sclerosis","Neuropathy","Diabetic Neuropathies","Alzheimer Disease","Dementia","Frontotemporal Dementia","Lewy Body Disease","Cognitive Impairment","Lewy Body Variant of Alzheimer Disease",[54,55,31,32,56,57,45,58,36,51,48,59],"Neurologic Disease","Cerebral Vascular Accident","Multiple Sclerosis","Parkinsons Disease","Diabetic Neuropathy","Neurodegeneration","RECRUITING","2026-06-24",{"date":63,"type":64},"2026-06-26","ACTUAL",{"date":66,"type":64},"2016-06",{"date":68,"type":21},"2028-07-31",{"name":70,"class":71},"MD Stem Cells","INDUSTRY",3,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":80,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":4,"leadSponsor":103,"locationsCount":106},"100078073","the-neurodevelopmental-and-behavioral-phenotyping-screening-protocol-100078073","NCT00271622","The Neurodevelopmental and Behavioral Phenotyping Screening Protocol","Neurodevelopmental and Behavioral Phenotyping Screening Protocol","* INCLUSION CRITERIA:\n* Subjects must be at least 6 weeks of age.\n* Subjects or their parents must be competent to comprehend the purpose of the screening process and to provide written informed consent. Parents\u002Fguardians will sign the consent form, and both minors and adults (depending on results of capacity assessment) will be asked to assent only if it is determined that they understand their role in the study.\n* Subjects must be willing to undergo an evaluation which may include a psychiatric interview; and medical, neurological, and laboratory examinations (as appropriate, such as renal and liver function tests, serum electrolytes, urinalysis, blood levels of psychotropic drugs, and urine drug screen for the presence of psychoactive drugs and drugs of abuse, as determined on a subject-to-subject basis).\n\nEXCLUSION CRITERIA:\n\n-Lack of appropriate consent: For minor patients, consent must be obtained from all legal guardians\u002Fcaretakers, including both parents in separated or divorced families where there is shared legal custody of the child. In such cases, both parents must consent to the child s participation in this protocol.",true,"6 Weeks",{"count":83,"type":21},5000,"OBSERVATIONAL","The purpose of this protocol is to allow for the careful evaluation of healthy volunteers and individuals with risk for psychiatric disorders or neurodevelopmental disorders, such as autism spectrum disorder for specific protocols at NIH.",[27,87,88,89],"Autism","Neurodegenerative Disease","Neurobehavioral Manifestation",[91,92,93,94,95,96,97,98],"Developmental Delay","Pediatric","Pervasive Developmental Disorder","Early Development","Healthy Control Subjects","Autism Spectrum Disorders","Healthy Volunteer","HV",{"date":100,"type":64},"2026-06-25",{"date":102,"type":64},"2006-02-27",{"name":104,"class":105},"National Institute of Mental Health (NIMH)","NIH",1,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":113,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":116,"conditions":117,"keywords":118,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":4,"leadSponsor":130,"locationsCount":106},"100062447","evaluation-and-treatment-of-neurosurgical-disorders-100062447","NCT00060541","Evaluation and Treatment of Neurosurgical Disorders","* INCLUSION CRITERIA:\n\n  1. Participants must be age 4 and older.\n  2. Participants must seek care from, or be referred to the Surgical Neurology Branch for evaluation and management of neurosurgical conditions (such as central nervous system tumors, peripheral nerve tumors, epilepsy, Parkinson s disease, movement disorders, Chiari syndrome, central nervous system malformations, and pain disorders)\n  3. For adults: able to provide informed consent or having a legally-authorized representative to provide consent, if incapacitated\n  4. For minors: a parent or legal guardian who is able to provide consent.\n\n     For immediate blood relatives of subjects having genetic testing only:\n  5. Blood relative of a subject who is suspected to have a genetic mechanism underlying their neurological disorder (for genetic testing only).\n\nEXCLUSION CRITERIA:\n\n1\\. Patients who are unable to undergo evaluation and treatment for a neurosurgical disorder\n\n3.c. Participant Inclusion Criteria for the cohort with processing of biological samples only (for those subjects who are only having skin biopsies and\u002For saliva samples)\n\n1. Participants must be age 4 and older.\n2. Participants must seek care from or be referred to the Surgical Neurology Branch for evaluation and management of neurosurgical conditions (such as central nervous system tumors, peripheral nerve tumors, epilepsy, Parkinson s disease, movement disorders, Chiari syndrome, central nervous system malformations, and pain disorders)\n3. For adults: able to provide informed consent or having a legally-authorized representative to provide consent, if incapacitated\n4. For minors: a parent or legal guardian who is able to provide consent.\n5. Be willing to consent for collection of clinical data or biological samples or their cryopreservation\n\n3.D. Participant Exclusion Criteria for the cohort with processing of biological samples only (for those subjects who are only having skin biopsies and\u002For saliva samples)\n\n1. Patients who are unable to undergo evaluation and treatment for a neurosurgical disorder\n2. At the time of enrollment, subjects without an established diagnosis of a wellcharacterized disease entity with validated treatment algorithms. In such cases, proposed resource investment, in the opinion of the investigators, would not contribute to further advancement of knowledge","4 Years","99 Years",{"count":83,"type":21},"Objective: This protocol is designed to allow evaluation of participants neurosurgical disorders that receive care within the Surgical Neurology Branch. The participants will receive standard-of-clinical-care evaluation and treatment. The clinical data and samples generated during standard of care treatment will be collected as a part of this study.\n\nStudy Population: Participants 4 years of age and older with neurosurgical-related conditions seeking care from, or referred to the Surgical Neurology Branch for evaluation are eligible for this protocol.\n\nStudy Design: This is an observational study. Participants will receive standard-of- clinical-care evaluation and treatment for their neurosurgical condition. Clinical evaluation may include laboratory and radiological studies designed to aid in diagnosis or differential diagnosis of the participant s condition or to facilitate treatment. The evaluations may take place in the outpatient clinic areas or in the inpatient units. Some participants will receive standard-of-care medical or surgical treatment for their disorder. Clinical data, tissue samples or body fluids obtained during standard of care treatment, may be used for research. Additional genetic testing may be performed on subjects and their blood relatives if a genetic mechanism underlying the neurological disorder is suspected. Patients in this study may choose to consent to skin biopsies for research purposes, in which case they will sign an additional consent document for thesethis research procedure.\n\nOutcome Measures: No additional research outcome measures will be tracked in this study, as this study is collecting data for potential future use. All outcomes will be those of standard clinical evaluation and treatment. A clinical and research database will be kept of patient s diagnosis, progression, and treatment. Clinical database information may be reported or be used in other studies.",[27],[119,120,121,122,123,124],"Brain Tumor","Epilepsy","Pituitary Adenoma","Parkinson's Disease","Spinal Cord Tumor","Natural History","2026-06-13",{"date":127,"type":64},"2026-06-16",{"date":129,"type":64},"2003-06-04",{"name":131,"class":105},"National Institute of Neurological Disorders and Stroke (NINDS)",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":142,"conditions":143,"keywords":145,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":106},"100614540","reliability-and-validity-of-the-prefs-100614540","NCT07280923","Reliability and Validity of the PReFS","Reliability and Validity of the Pressure Relief Frequency Scale","PReFS","Inclusion Criteria:\n\n* primary wheelchair user\n* diagnosed with a neurologic disorder\n\nExclusion Criteria:\n\n* does not use a wheelchair for more than 50% of waking hours",{"count":141,"type":21},15,"This study is testing the psychometric properties of a new tool to determine recommendations for pressure relief frequency in wheelchair users.",[27,144,31,32],"Spinal Cord Injury",[146,147,148],"wheelchair user","pressure relief","skin integrity","2025-12-17",{"date":151,"type":64},"2025-12-23",{"date":153,"type":21},"2025-12",{"date":155,"type":21},"2027-01",{"name":157,"class":158},"Baylor University","OTHER",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":80,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":22,"phases":169,"briefSummary":170,"conditions":171,"keywords":175,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":72},"100615672","characterization-of-high-level-cognitive-impairments-in-patients-with-neuropsychiatric-disorders-100615672","NCT07295652","Characterization of High-Level Cognitive Impairments in Patients With Neuropsychiatric Disorders","Characterization of High-level Cognitive Impairments in Patients With Neuropsychiatric Disorders","COGPSY","Inclusion Criteria:\n\nFor patients:\n\n* Aged over 18 years\n* Diagnosed with a psychiatric disorder according to ICD-10 by a psychiatrist (F10-F98) or diagnosed with a neurological disorder according to ICD-10 by a neurologist (G00-G99)\n* Provided written informed consent\n* Affiliated with a social security scheme\n\nFor healthy volunteers:\n\n* Aged over 18 years\n* Provided written informed consent\n* Affiliated with a social security scheme\n\nExclusion Criteria:\n\nFor healthy volunteers:\n\n* Current diagnosis of a psychiatric disorder according to ICD-10 (F20-F98) or current prescription of a psychotropic medication, or diagnosis of a neurological disorder according to ICD-10 (G00-G99)\n* History of depression (F32)\n* Substance use disorder (excluding tobacco)\n* Neurological history (e.g., stroke, coma, epilepsy, neuroinflammatory or neurodegenerative disease) or identified cognitive disorder\n* Inability to complete cognitive testing (e.g., due to motor or sensory impairment)\n\nFor participants undergoing MRI (without contrast agent):\n\n* Presence of MRI contraindications: non-MRI-compatible pacemaker, heart valve, implant, or metallic foreign body\n* Pregnancy at the time of MRI",{"count":168,"type":21},600,[24],"Neuropsychiatric disorders are extremely common, severe, and disabling conditions. In the field of psychiatry, they notably include schizophrenia, mood disorders (depressive and bipolar disorders), autism spectrum or neurodevelopmental disorders, obsessive-compulsive disorder, eating disorders, and personality disorders. In the field of neurology, one can cite neurodegenerative diseases (such as Alzheimer's disease, but also frontotemporal dementia or Parkinson's disease, which often represent frequent and challenging differential diagnoses of psychiatric disorders), focal neurological lesions (notably strokes and tumors), or epilepsy.\n\nCognitive impairments are present in nearly all neuropsychiatric disorders and contribute significantly to disability.\n\nWhile impairments in working memory and attention, executive functions, and social cognition have been relatively well studied, other cognitive domains remain largely unexplored in these populations. This is particularly the case for various aspects of motivation, metacognition, conscious access, or causal (Bayesian) inference.\n\nAlthough these domains likely play an important role in prognosis, no consensus currently exists regarding the methods for evaluating these functions.\n\nThe main objective of this study is to define a multidimensional, transdiagnostic atlas of high-level cognitive impairments-both specific and shared-across severe psychiatric disorders (notably schizophrenia, depressive disorder, bipolar disorder, autism spectrum or neurodevelopmental disorders, and obsessive-compulsive disorder) and neurological disorders (notably neurodegenerative diseases, focal neurological lesions, and epilepsy), by comparing them to healthy volunteers.\n\nThe investigators also aim to investigate the progression of cognitive impairments over time, across different phases of illness (symptom stabilization or exacerbation) or therapeutic intervention, through longitudinal follow-up of patients being monitored within the recruiting center.\n\nFinally, in a more exploratory manner, the investigators aim to investigate the neural correlates of the identified cognitive impairments.",[27,172,173,174],"Schizophrenia","Bipolar Disorder (BD)","Depressive Disorder",[176,177,178,179,180,181,182,183,184,185],"Cognitive dysfunction","Executive function","Metacognition","Motivation","Social cognition","Transdiagnostic approach","High-level cognition","Longitudinal cognitive changes","Cognitive profiling","Differential diagnosis","2025-12-16",{"date":188,"type":64},"2025-12-19",{"date":190,"type":64},"2024-03-12",{"date":192,"type":21},"2039-03",{"name":194,"class":158},"Centre Hospitalier St Anne",{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":80,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":22,"phases":203,"briefSummary":206,"conditions":207,"keywords":218,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":106},"100415052","phase-1-mesenchymal-stem-cells-for-the-treatment-of-various-chronic-and-acute-conditions-100415052","NCT04684602","Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions","Evaluation of the Safety, Tolerability and Efficacy of Regenerative Therapy for the Treatment of Various Chronic and Acute Conditions","Inclusion Criteria:\n\n* Age 18 and older\n* Ability to provide informed consent\n* Availability for follow up visits\n\nExclusion Criteria:\n\n* Active or recent malignancy (within last 2 years)\n* Pregnancy or breast-feeding\n* Inability to provide informed consent",{"count":83,"type":21},[204,205],"PHASE1","PHASE2","This multi-arm, multi-site study investigates the safety, tolerability, and efficacy of stem cell therapy for the treatment of various acute and chronic conditions. Clinically observed initial findings and an extensive body of research indicate regenerative treatments are both safe and effective for the treatment of multiple conditions.",[208,209,210,211,212,213,27,214,215,216,217],"Autoimmune Diseases","Cardiovascular Disorders","Diabetes Complications","Integumentary Disease","Musculoskeletal Disorders","Neurodegenerative Disorders","Pulmonary Disorders","Sexual Dysfunction","Urologic Disorders","Viral Illness",[219,220,221,222,223,224,225,226,227,228,229,29,230,231,232,48,233,234,235,236,28,47,237,238,239,240,241],"stem cell therapy","umbilical cord stem cells","amniotic stem cells","stem cells","MSC","Mesenchymal Stem Cell","Medicinal Signaling Cell","Erectile Dysfunction","Heart Diseases","Mental Disorders","Neurocognitive Disorders","Central Nervous System Diseases","Tauopathies","Brain Diseases","Disease","Cardiomyopathies","Urologic Diseases","Peripheral Nervous System Diseases","Musculoskeletal Diseases","Cardiovascular Diseases","Immune System Diseases","Neuromuscular Diseases","Covid-19","2022-04-27",{"date":244,"type":64},"2022-04-29",{"date":246,"type":64},"2020-07-09",{"date":248,"type":21},"2030-12-09",{"name":250,"class":71},"Thomas Advanced Medical LLC"]